Abbott Laboratories, Q4

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings.
Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year that was below market expectations.The stock was down 0.2% Wednesday while the S&P 500 futures was up 0.
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Abbott Laboratories (NYSE: ABT) Q4 2024 Earnings Call Jan 22, 2025, 9:30 a.m. ET
Abbott Laboratories slips after Q4 topline miss
Abbott Laboratories (ABT) stock traded lower in the premarket on Wednesday after its Q4 2024 results fell short of Street forecasts for revenue. Read more here.
Abbott Laboratories Q4 Profit Increases, Inline With Estimates
Abbott Laboratories (ABT) revealed a profit for its fourth quarter that increased from last year in line with the Street estimates.
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks Consensus Estimate. However, the figure improved 12.6% from the prior-year quarter’s level.
Abbott’s 2025 Profit Forecast Meets Estimates on Device Demand
Abbott Laboratories is forecasting profit for 2025 in line with Wall Street’s estimates as the health care company said strong demand for its medical devices will continue to drive growth.
Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit
Abbott stock fell early Wednesday after the health giant narrowly missed fourth-quarter sales views and reported in-line profit.
Abbott (ABT) Q4 Earnings Meet Estimates
Abbott (ABT) came out with quarterly earnings of $1.34 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.19 per share a year ago. These figures are adjusted for non-recurring items.
Abbott Laboratories stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Hosted on MSN14h
Abbott Laboratories Reports Strong 2024 Financial Results
Abbott Laboratories ( ($ABT) ) has released its Q4 earnings. Here is a breakdown of the information Abbott Laboratories ...
Abbott Laboratories: Solid Performance in Key Sectors but Hold Rating Due to Mixed Outlook
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
Abbott Laboratories: Strong Performance and Promising Outlook Support Buy Rating
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...
Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
Abbott banks on glucose monitors, new launches to ride out China, currency hit
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street estimates, along with weak fourth-quarter ...
Abbott Laboratories’ Growth Prospects and Market Leadership in MedTech Justify Buy Rating
BTIG analyst Marie Thibault maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...